Patrick G. Enright, Director, 10% Owner at Aimmune Therapeutics, Inc. (AIMT), bought 15,593 shares at $32.00 ($499K) on 2018-02-22, disclosed to the SEC on 2018-02-26.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| ZBIO | BUY | 2025-10-14 | $2.5M | — | Filing → |
| VERA | BUY | 2025-06-25 | $10.6M | — | Filing → |
| BIOA | BUY | 2024-09-27 | $7.2M | — | Filing → |